Form 4: Ocular Therapeutix Chief Scientific Officer Sells Shares to Cover Tax Obligations
Insider Transaction Report
Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc., sold 3,024 shares of common stock at a weighted average price of $7.18 to satisfy tax withholding obligations related to restricted stock unit vesting.
Summary
- Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc. (OCUL), sold 3,024 shares of the company's common stock.
- The shares were sold on May 23, 2025, at a weighted average price of $7.18 per share, with individual transaction prices ranging from $7.06 to $7.29.
- This transaction was executed pursuant to a pre-arranged Rule 10b5-1 plan, a durable automatic sale instruction adopted by Mr. Heier on April 9, 2024.
- The sale was a 'sell-to-cover' election specifically to satisfy tax withholding obligations associated with the vesting of restricted stock units on May 22, 2025, and does not represent a discretionary trade by Mr. Heier.
- Following this transaction, Mr. Heier beneficially owns 262,974 shares of Ocular Therapeutix common stock.
Sentiment
Score: 5
Explanation: The transaction is neutral as it is a non-discretionary sale to cover tax obligations from RSU vesting, rather than a discretionary sale indicating a change in insider sentiment or company outlook.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on an insider transaction.
Management Comments
- The sales do not represent a discretionary trade by the reporting person.
Industry Context
This Form 4 filing details a routine insider transaction for tax purposes, which is a common occurrence across all industries, particularly for executives receiving equity compensation. It does not provide specific insights into broader industry trends or competitive dynamics within the biopharmaceutical or ophthalmology sectors.
Stakeholder Impact
- Shareholders: Minimal direct impact as the sale is non-discretionary and for tax purposes, not indicative of a change in management's outlook on the company's prospects.
- Employees: No direct impact.
Key Dates
| Date | Description |
|---|---|
| 04/09/2024 | Date the reporting person adopted the durable automatic sale instruction (Rule 10b5-1 plan). |
| 05/22/2025 | Date of vesting of restricted stock units, which triggered the tax withholding obligations. |
| 05/23/2025 | Date of the reported transaction (sale of common stock). |
| 05/27/2025 | Date the Form 4 was filed with the SEC. |
Keywords
Ocular Therapeutix, OCUL, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Jeffrey S. Heier, Chief Scientific Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.